CD19 and acute lymphoblastic leukemia: The most impressive responses have been achieved in patients with B cell malignancy, especially in refractory or relapsed B acute lymphoblastic leukemia (B-ALL) treated by CAR T cells targeting CD19 with the complete remission (CR) rate reaching 90% [2–5].